Pura Vida Investments, LLC Oncocyte Corp Transaction History

Pura Vida Investments, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.2 - $0.35 $108,228 - $189,399	-541,141 Reduced 3.82%	13,625,022 $3.13 Million
Q1 2023 May 15, 2023	SELL	$0.2 - $0.49 $778,022 - $1.91 Million	-3,890,111 Reduced 21.54%	14,166,163 $4.96 Million
Q2 2022 Aug 15, 2022	BUY	$0.86 - $1.53 $5.02 Million - $8.92 Million	5,832,321 Added 47.71%	18,056,274 $16.2 Million
Q1 2021 May 12, 2021	BUY	$2.39 - $6.5 $14.2 Million - $38.6 Million	5,941,130 Added 94.56%	12,223,953 $63.4 Million
Q4 2020 Feb 16, 2021	BUY	$1.38 - $2.63 $359,198 - $684,560	260,289 Added 4.32%	6,282,823 $15 Million

Q3 2020 Nov 16, 2020	BUY	$1.2 - $1.89 $46,572 - $73,350	38,810 Added 0.65%	6,022,534 $8.37 Million
Q2 2020 Aug 14, 2020	BUY	$1.91 - $3.45 $774,392 - $1.4 Million	405,441 Added 7.27%	5,983,724 $11.4 Million
Q1 2020 May 15, 2020	SELL	$1.76 - $3.02 $208,195 - $357,244	-118,293 Reduced 2.08%	5,578,283 $13.7 Million
Q4 2019 Feb 12, 2021	BUY	$1.51 - $2.27 $4.16 Million - $6.25 Million	2,755,400 Added 93.68%	5,696,576 $12.8 Million
Q4 2019 Feb 14, 2020	BUY	$1.51 - $2.27 $4.44 Million - $6.68 Million	2,941,176 New	2,941,176 $6.62 Million

1.16M

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $350M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Pura Vida Investments, LLC with notifications on news.